Orange, CANCT04920032Now EnrollingIRB Ready

Colon Adenocarcinoma Clinical Trial in Orange, CA

Access cutting-edge colon adenocarcinoma treatment through this clinical trial at a research site in Orange. Study-provided care at no cost to qualified participants.

Sponsored by University of California, Irvine

Quick Self-Assessment

See if you qualify for this Orange location

Preparing your pre-screening questions…

Expert Care in Orange

Access colon adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related colon adenocarcinoma treatment provided free

Apply for This Orange Location

Check if you qualify for this colon adenocarcinoma clinical trial in Orange, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Orange

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Orange site if eligible
  4. 4Begin participation

About This Colon Adenocarcinoma Study in Orange

This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.

Sponsor: University of California, Irvine

Who Can Participate

Inclusion Criteria

Patients must have histologically or cytologically confirmed adenocarcinoma of the colon (high rectal cancer is eligible if resected and no radiation needed). Other histologies which are treated per NCCN guidelines for adjuvant colon cancer are eligible.
Must have Stage II, Stage III, or Stage IV colorectal cancer after curative intent resection eligible for adjuvant doublet chemotherapy for at least 3 months.
Must have ctDNA positive assay (tested by Signatera MRD assay) after at least 3 months of perioperative chemotherapy
Age ≥ 18 years
Performance status: ECOG performance status ≤2
Life expectancy of greater than 3 months
Adequate organ and marrow function as defined below:
leukocytesL ≥ 3,000/mcL
absolute neutrophil count: ≥ 1,500/mcL
platelets: ≥ 80,000/mcl
total bilirubin: within normal institutional limits
AST(SGOT)/ALT(SPGT): ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present
creatinine: \<1.5 X ULN
The effects of TAS-102 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because topoisomerase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. a. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
Has not undergone a hysterectomy or bilateral oophorectomy; or
Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
Ability to swallow tablets
Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria

Patients who have had major surgery within 4 weeks, or chemotherapy or radiotherapy within 2 weeks prior to Cycle 1 Day 1
All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline
Patients may not be receiving any other investigational agents.
Patients with known metastases.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102, irinotecan or other agents used in study.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Prior treatment with TAS-102 at any time or irinotecan within 90 days from enrollment.
History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ.
Inability to comply with study and follow-up procedures as judged by the Investigator
Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants. -

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Orange?

Yes, this clinical trial (NCT04920032) has an active research site in Orange, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Colon Adenocarcinoma Treatment Options in Orange, CA

If you're searching for colon adenocarcinoma treatment options in Orange, CA, this clinical trial (NCT04920032) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Orange research site is actively enrolling participants for this clinical trial. You'll receive care from experienced colon adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all colon adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Orange, CA

See all alzheimers disease clinical trials recruiting in Orange — not just this study.

Browse Alzheimers Disease Trials in Orange →

Browse More Trials by Condition

Alzheimers Disease TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Orange?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Orange, CA